Pharm Exec1h
Jelmyto Demonstrates Significant Recurrence-Free Survival Rate at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer
Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with Jelmyto.
Pharm Exec3h
FDA Approves Two Generics from Amneal Pharmaceuticals for Alzheimer and Oncology, with Tentative Approval for Gastrointestinal Disease
As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in patients with Alzheimer disease, with Everolimus receiving approval for ...
Pharm Exec4h
Viralgen and Axovia Partner to Manufacture Gene Therapy for Retinal Dystrophy in Bardet-Biedl Syndrome Patients
Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) caused by biallelic ...
Pharm Exec9h
Arvinas Announces Interim Chief Commercial Officer
Arvinas, Inc, announced that its chief commercial officer, John Northcott, is stepping down as of mid-January. 1 While the ...
Pharm Exec9h
The Ups and Downs of AI for Pharma Investors
Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.